A new, topical small molecule drug candidate shows promise for the treatment of androgenetic alopecia, having performed well in phase 2a clinical trials. TDM-105795 from Technoderma Medicines, Inc. is potent thyromimetic that has poor systemic absorption following topical application and a short elimination half-life.
The early phase study in 71 men assessed non-vellus Target Area Hair Count (TAHC), with mean changes from baseline of 24.3 hairs 0.02% formulation and 20.3 hairs with the 0.0025% topical solution. This is compared to 14.0 hairs with placebo in 1 cm2 test areas. Both strengths of TDM-105795 were well tolerated with no material safety issues identified.
TDM-105795 was applied once-daily. Bioanalytical results show extremely low to no systemic exposure.
Technoderma says it looks forward to moving the clinical program forward. “This is another major milestone for the Company that further increases confidence in our pipeline programs to produce and develop clinically useful new chemical entities in dermatology,” said Zengquan Wang, PhD, Chief Executive Officer at Technoderma. “We are committed to developing a portfolio of innovative dermatology drug candidates.”